Cargando…

Approach to the Patient: “Utility of the Copeptin Assay”

Copeptin derives from the same precursor peptide preprovasopressin as arginine vasopressin (AVP). The secretion of both peptides is stimulated by similar physiological processes, such as osmotic stimulation, hypovolemia, or stress. AVP is difficult to measure due to complex preanalytical requirement...

Descripción completa

Detalles Bibliográficos
Autores principales: Christ-Crain, Mirjam, Refardt, Julie, Winzeler, Bettina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113794/
https://www.ncbi.nlm.nih.gov/pubmed/35137148
http://dx.doi.org/10.1210/clinem/dgac070
_version_ 1784709646518321152
author Christ-Crain, Mirjam
Refardt, Julie
Winzeler, Bettina
author_facet Christ-Crain, Mirjam
Refardt, Julie
Winzeler, Bettina
author_sort Christ-Crain, Mirjam
collection PubMed
description Copeptin derives from the same precursor peptide preprovasopressin as arginine vasopressin (AVP). The secretion of both peptides is stimulated by similar physiological processes, such as osmotic stimulation, hypovolemia, or stress. AVP is difficult to measure due to complex preanalytical requirements and due to technical difficulties. In the last years, copeptin was found to be a stable, sensitive, and simple to measure surrogate marker of AVP release. Different immunoassays exist to measure copeptin. The 2 assays which have most often be used in clinical studies are the original sandwich immunoluminometric assay and its automated immunofluorescent successor. In addition, various enzyme-linked immunosorbent assay have been developed. With the availability of the copeptin assay, the differential diagnosis of diabetes insipidus was recently revisited. The goal for this article is therefore to first review the physiology of copeptin, and second to describe its use as marker for the differential diagnosis of vasopressin-dependent fluid disorders, mainly diabetes insipidus but also hyper- and hyponatremia. Furthermore, we highlight the role of copeptin as prognostic marker in other acute and chronic diseases.
format Online
Article
Text
id pubmed-9113794
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91137942022-05-18 Approach to the Patient: “Utility of the Copeptin Assay” Christ-Crain, Mirjam Refardt, Julie Winzeler, Bettina J Clin Endocrinol Metab Approach to the Patient Copeptin derives from the same precursor peptide preprovasopressin as arginine vasopressin (AVP). The secretion of both peptides is stimulated by similar physiological processes, such as osmotic stimulation, hypovolemia, or stress. AVP is difficult to measure due to complex preanalytical requirements and due to technical difficulties. In the last years, copeptin was found to be a stable, sensitive, and simple to measure surrogate marker of AVP release. Different immunoassays exist to measure copeptin. The 2 assays which have most often be used in clinical studies are the original sandwich immunoluminometric assay and its automated immunofluorescent successor. In addition, various enzyme-linked immunosorbent assay have been developed. With the availability of the copeptin assay, the differential diagnosis of diabetes insipidus was recently revisited. The goal for this article is therefore to first review the physiology of copeptin, and second to describe its use as marker for the differential diagnosis of vasopressin-dependent fluid disorders, mainly diabetes insipidus but also hyper- and hyponatremia. Furthermore, we highlight the role of copeptin as prognostic marker in other acute and chronic diseases. Oxford University Press 2022-02-08 /pmc/articles/PMC9113794/ /pubmed/35137148 http://dx.doi.org/10.1210/clinem/dgac070 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Approach to the Patient
Christ-Crain, Mirjam
Refardt, Julie
Winzeler, Bettina
Approach to the Patient: “Utility of the Copeptin Assay”
title Approach to the Patient: “Utility of the Copeptin Assay”
title_full Approach to the Patient: “Utility of the Copeptin Assay”
title_fullStr Approach to the Patient: “Utility of the Copeptin Assay”
title_full_unstemmed Approach to the Patient: “Utility of the Copeptin Assay”
title_short Approach to the Patient: “Utility of the Copeptin Assay”
title_sort approach to the patient: “utility of the copeptin assay”
topic Approach to the Patient
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113794/
https://www.ncbi.nlm.nih.gov/pubmed/35137148
http://dx.doi.org/10.1210/clinem/dgac070
work_keys_str_mv AT christcrainmirjam approachtothepatientutilityofthecopeptinassay
AT refardtjulie approachtothepatientutilityofthecopeptinassay
AT winzelerbettina approachtothepatientutilityofthecopeptinassay